ARS Pharmaceuticals, Inc.
SPRYNasdaq
$7.00
↓ -6.2%Jul 17 close · end-of-day
Price
1Y↓ -60.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$695.1M
Enterprise Value
$590.6M
P/E
—
P/S
7.0
P/B
11.3
EV/EBITDA
—
PEG
—
FCF Yield
-25.2%
Dividend Yield
—
Revenue (TTM)
$99.0M
Net Income (TTM)
-$198.0M
Free Cash Flow (TTM)
-$175.3M
Gross Margin
—
Operating Margin
-204.5%
Net Margin
-200.0%
ROE
-322.9%
ROIC
—
Debt / Equity
1.6
Net Cash
$104.4M
Return 1Y
-61.9%
Company profile
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
- CEO
- Richard E. Lowenthal
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 90
- Headquarters
- California
- Website
- ars-pharma.com
Earnings
SPRY Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$22.7M↑ +184.5%
Diluted EPS-$0.61↑ +74.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $5.5M | $1.3M | $30,000.00 | $89.1M | $84.3M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$32.9M | -$19.5M | -$35.5M | -$67.5M | -$3.1M | -$179.4M |
| Net income | -$32.9M | -$20.2M | -$34.7M | -$54.4M | $8.0M | -$171.3M |
| Diluted EPS | — | -$0.70 | -$0.87 | -$0.57 | $0.08 | -$1.74 |
| Operating cash flow | -$31.2M | -$17.6M | -$40.1M | -$59.3M | $13.5M | -$170.9M |
| Free cash flow | -$32.1M | -$17.6M | -$40.3M | -$59.4M | $13.0M | -$171.2M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | -353.3% | -2698.8% | -225066.7% | -3.5% | -212.9% |
| Net margin | — | -367.7% | -2635.4% | -181216.7% | 9.0% | -203.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $500,000.00 | $2.1M | $86.6M | $8.0M | $15.7M | $32.5M | $28.1M | $22.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$15.3M | -$21.7M | $47.2M | -$37.2M | -$47.6M | -$53.2M | -$41.5M | -$60.1M |
| Net income | -$12.5M | -$19.1M | $49.9M | -$33.9M | -$44.9M | -$51.2M | -$41.3M | -$60.6M |
| Diluted EPS | -$0.13 | -$0.20 | $0.52 | -$0.35 | -$0.46 | -$0.52 | -$0.41 | -$0.61 |
| Operating cash flow | -$7.3M | -$14.5M | $42.0M | -$40.7M | -$39.6M | -$47.0M | -$43.5M | -$44.9M |
| Free cash flow | -$7.3M | -$14.6M | $41.7M | -$40.8M | -$39.6M | -$47.2M | -$43.5M | -$44.9M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -3068.0% | -1051.6% | 54.5% | -466.3% | -302.9% | -163.7% | -147.6% | -265.2% |
| Net margin | -2503.2% | -925.0% | 57.7% | -425.7% | -285.6% | -157.4% | -147.1% | -267.3% |
Company news
Jun 25, 2026
- 24d agoARS Pharma Collapses After CVS Punts Its Epinephrine Spray Decision To Januaryfinance.yahoo.com
- 25d agoMicron Sparks Fresh AI Stock Rallyfinance.yahoo.com
- 25d agoSPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Todaystocktwits.com
- 25d agoSPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffystocktwits.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.